Mérot Y, Camenzind M, Geiger J M, Saurat J H
Acta Derm Venereol. 1987;67(3):237-42.
The arotinoid ethyl ester Ro 13-6298 is a third generation retinoid shown to be thousand-fold more potent than etretinate (Tigason, Tegison) in animal testing and in human therapy. In an open uncontrolled trial, we treated 57 patients suffering from psoriasis (32) and various severe skin disorders (25) with daily doses ranging from 20 to 150 micrograms, during 1 to 130 weeks (mean = 12 weeks). Four patients were treated for 1 year or more. Given in micrograms per kg range, Ro 13-6298 showed a spectrum of clinical activity and mucocutaneous side effects similar to that of etretinate given in mg per kg range. One patient developed diffuse idiopathic skeletal hyperostosis after 2 years of continuous therapy. No increase in either serum triglycerides or cholesterol levels was observed, even in patients treated for 33 to 130 weeks. This might prove to be an advantage of this new retinoid. Furthermore, this series suggests that potent mucocutaneous (therapeutical and side) effects are not necessarily linked to all other signs of retinoid toxicity.
芳维甲酸乙酯Ro 13 - 6298是第三代维甲酸，在动物试验和人体治疗中显示出比依曲替酯（银屑灵，Tigason，Tegison）强一千倍的效力。在一项开放的非对照试验中，我们用每日20至150微克的剂量治疗了57例银屑病患者（32例）和各种严重皮肤病患者（25例），疗程为1至130周（平均= 12周）。4例患者治疗了1年或更长时间。以每千克微克数给药时，Ro 13 - 6298显示出的临床活性谱和黏膜皮肤副作用与以每千克毫克数给药的依曲替酯相似。1例患者在持续治疗2年后出现弥漫性特发性骨肥厚。即使在治疗33至130周的患者中，也未观察到血清甘油三酯或胆固醇水平升高。这可能证明是这种新型维甲酸的一个优势。此外，该系列研究表明，强效的黏膜皮肤（治疗性和副作用）效应不一定与维甲酸毒性的所有其他体征相关。
